Akoya Biosciences Inc expected to post a loss of 20 cents a share - Earnings Preview

Akoya Biosciences

10/05/2025 24:54

Akoya Biosciences Inc AKYA.OQ AKYA.O is expected to show a rise in quarterly revenue when it reports  results on May 12 (estimated) for the period ending March 31 2025

The Marlborough Massachusetts-based  company is expected to report a 8.7% increase in revenue to $19.949 million from $18.35 million a year ago, according to the mean estimate from 7 analysts, based on LSEG data.

​LSEG's mean analyst estimate for Akoya Biosciences Inc is for a loss of 20 cents per share.

The current average analyst rating on the shares is "hold" and the breakdown of recommendations is no "strong buy" or "buy," 8 "hold" and no "sell" or "strong sell."

The mean earnings estimate of analysts was unchanged in the last three months. ​

Wall Street's median 12-month price target for Akoya Biosciences Inc is $3.00​, above​ its last closing price of $1.10. ​​​

Previous quarterly performance (using preferred earnings measure in US dollars). ​

QUARTER ENDING
STARMINESMARTESTIMATE®
LSEG IBES ESTIMATE
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Dec. 31 2024
-0.16
-0.16
-0.17
Missed
-4.6
Sep. 30 2024
-0.20
-0.20
-0.21
Missed
-3.1
Jun. 30 2024
-0.27
-0.27
-0.27
Met
-0.8​
Mar. 31 2024
-0.29
-0.29
-0.48
Missed
-66.2
​​Dec. 31 2023
-0.27
-0.27
-0.22
Beat
18.1
Sep. 30 2023
-0.36
-0.37
-0.26
Beat
28.9​
Jun. 30 2023
-0.43
-0.44
-0.46
Missed
-3.9
Mar. 31 2023
-0.50
-0.48
-0.49
Missed
-1.5

This summary was machine generated May 9 at 23:54 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)